Patient engagement in drug development: configuring a new resource for generating innovation

References

• Asdal, K., & Reinertsen, H. (2022). Doing document analysis: A practice-oriented method. SAGE.
   Google Scholar
• Carman, K. L., Dardess, P., Maurer, M., Sofaer, S., Adams, K., Bechtel, C., & Sweeney, J. (2013). Patient and family engagement: A framework for understanding the elements and developing interventions and policies. Health Affairs, 32(2), 223–231. https://doi.org/10.1377/hlthaff.2012.1133
   PubMed Web of Science ®Google Scholar
• Cavaller-Bellaubi, M., Faulkner, S. D., Teixeira, B., Boudes, M., Molero, E., Brooke, N., McKeaveney, L., Southerton, J., Vicente, M. J., Bertelsen, N., García-Burgos, J., Pirard, V., Reid, K., & Ferrer, E. (2021). Sustaining meaningful patient engagement across the lifecycle of medicines: A roadmap for action. Therapeutic Innovation & Regulatory Science, 55(5), 936–953. https://doi.org/10.1007/s43441-021-00282-z
   PubMed Web of Science ®Google Scholar
• Chalasani, M., Vaidya, P., & Mullin, T. (2018). Enhancing the incorporation of the patient’s voice in drug development and evaluation. Research Involvement and Engagement, 4(1), 10. https://doi.org/10.1186/s40900-018-0093-3
   PubMedGoogle Scholar
• Feldman, D., Kruger, P., Delbecque, L., Duenas, A., Bernard-Poenaru, O., Wollenschneider, S., Hicks, N., Reed, J. A., Sargeant, I., Pakarinen, C., Hamoir, A.-M., on behalf of Patient Focused Medicines Development Working Groups 1, Bernard-Poenaru, O., Deane, K., Feldman, D., Fox, G., Oleksandr, G., Hartke, J., Hicks, N., & Escudier, T. (2021). Co-creation of practical “how-to guides” for patient engagement in key phases of medicines development—from theory to implementation. Research Involvement and Engagement, 7(1), 57. https://doi.org/10.1186/s40900-021-00294-x
   PubMedGoogle Scholar
• Cook, N. S., Cave, J., & Holtorf, A. -P. (2019). Patient preference studies during early drug development: Aligning stakeholders to ensure development plans meet patient needs. Frontiers in Medicine, 6, 82. https://doi.org/10.3389/fmed.2019.00082
   Web of Science ®Google Scholar
• Cooper, M. (2012). The pharmacology of distributed experiment – user-generated drug innovation. Body & Society, 18(3–4), 18–43. https://doi.org/10.1177/1357034X12446380
   Web of Science ®Google Scholar
• Dellson, P., Nilsson, K., Jernstrom, H., & Carlsson, C. (2018). Patients’ reasoning regarding the decision to participate in clinical cancer trials: An interview study. Trials, 19(1), 528. https://doi.org/10.1186/s13063-018-2916-9
   PubMed Web of Science ®Google Scholar
• Dent, M., & Pahor, M. (2015). Patient involvement in Europe – A comparative framework. Journal of Health Organization and Management, 29(5), 546–555. https://doi.org/10.1108/JHOM-05-2015-0078
   PubMed Web of Science ®Google Scholar
• Dumit, J. (2012). Drugs for life: Growing health through facts and pharmaceuticals. Duke University Press.
   Google Scholar
• EUPATI. (n.d.). History. Retrieved February 1, 2022, from https://eupati.eu/about-us/history/
   Google Scholar
• Fabbri, A., Parker, L., Colombo, C., Mosconi, P., Barbara, G., Frattaruolo, M. P., Lau, E., Kroeger, C. M., Lunny, C., Salzwedel, D. M., & Mintzes, B. (2020). Industry funding of patient and health consumer organisations: Systematic review with meta-analysis. The BMJ, 368, l6925. https://doi.org/10.1136/bmj.l6925
   PubMedGoogle Scholar
• Fishman, J. R. (2004). Manufacturing desire: The commodification of female sexual dysfunction. Social Studies of Science, 34(2), 187–218. https://doi.org/10.1177/0306312704043028
   PubMed Web of Science ®Google Scholar
• Fox, N. J., & Ward, K. J. (2008). Pharma in the bedroom … and the kitchen … the pharmaceuticalisation of daily life. Sociology of Health & Illness, 30(6), 856–868. https://doi.org/10.1111/j.1467-9566.2008.01114.x
   PubMed Web of Science ®Google Scholar
• Frankish, C. J., Kwan, B., Ratner, P. A., Higgins, J. W., & Larsen, C. (2002). Challenges of citizen participation in regional health authorities. Social Science & Medicine, 54(10), 1471–1480. https://doi.org/10.1016/S0277-9536(01)00135-6
   PubMed Web of Science ®Google Scholar
• Fredriksson, M. (2013). Is patient choice democratizing Swedish primary care? Health Policy, 111(1), 95–98. https://doi.org/10.1016/j.healthpol.2012.12.002
   PubMed Web of Science ®Google Scholar
• Fugh-Berman, A., & Ahari, S. (2007). Following the script: How drug reps make friends and influence doctors. PLoS Medicine, 4(4), e150. https://doi.org/10.1371/journal.pmed.0040150
   PubMed Web of Science ®Google Scholar
• Getz, K. (2019). Reflections on the evolution of patient engagement in drug development. Pharmaceutical Medicine, 33(3), 179–185. https://doi.org/10.1007/s40290-019-00284-1
   PubMed Web of Science ®Google Scholar
• Godskesen, T. M., Kihlbom, U., Nordin, K., Silen, M., & Nygren, P. (2016). Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials. European Journal of Cancer Care, 25(3), 516–523.
   PubMed Web of Science ®Google Scholar
• Hansen, M. B., Nørgaard, L. S., & Hallgreen, C. E. (2020). How and why to involve patients in drug development: Perspectives from the pharmaceutical industry, regulatory authorities, and patient organizations. Therapeutic Innovation & Regulatory Science, 54(3), 577–585. https://doi.org/10.1007/s43441-019-00090-6
   PubMed Web of Science ®Google Scholar
• Hoos, A., Anderson, J., Boutin, M., Dewulf, L., Geissler, J., Johnston, G., Joos, A., Metcalf, M., Regnante, J., Sargeant, I., Schneider, R. F., Todaro, V., & Tougas, G. (2015). Partnering with patients in the development and lifecycle of medicines: A call for action. Therapeutic Innovation & Regulatory Science, 49(6), 929–939. https://doi.org/10.1177/2168479015580384
   PubMed Web of Science ®Google Scholar
• Latimer, T., Roscamp, J., & Papanikitas, A. (2017). Patient-centredness and consumerism in healthcare: An ideological mess. Journal of the Royal Society of Medicine, 110(11), 425–427. https://doi.org/10.1177/0141076817731905
   PubMed Web of Science ®Google Scholar
• Light, D. W., & Lexchin, J. R. (2012). Pharmaceutical research and development: What do we get for all that money? The BMJ, 345(aug07 1), e4348. https://doi.org/10.1136/bmj.e4348
   PubMedGoogle Scholar
• LoRusso, S., Johnson, N. E., McDermott, M. P., Eichinger, K., Butterfield, R. J., Carraro, E., Higgs, K., Lewis, L., Mul, K., Sacconi, S., Sansone, V. A., Shieh, P., van Engelen, B., Wagner, K., Wang, L., Statland, J. M., & Tawil, R. (2019). Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): Protocol of a large, international, multi-center prospective study. BMC Neurology, 19(1), 224. https://doi.org/10.1186/s12883-019-1452-x
   PubMed Web of Science ®Google Scholar
• Lowe, M. M., Blaser, D. A., Cone, L., Arcona, S., Ko, J., Sasane, R., & Wicks, P. (2016). Increasing patient involvement in drug development. Value in Health, 19(6), 869–878. https://doi.org/10.1016/j.jval.2016.04.009
   PubMed Web of Science ®Google Scholar
• Lupton, D. (2014). The commodification of patient opinion: The digital patient experience economy in the age of big data. Sociology of Health & Illness, 36(6), 856–869. https://doi.org/10.1111/1467-9566.12109
   PubMed Web of Science ®Google Scholar
• Martin, G. P. (2008). ‘Ordinary people only’: Knowledge, representativeness, and the publics of public participation in healthcare. Sociology of Health & Illness, 30(1), 35–54. https://doi.org/10.1111/j.1467-9566.2007.01027.x
   PubMed Web of Science ®Google Scholar
• Mulinari, S., Vilhelmsson, A., Rickard, E., & Ozieranski, P. (2020). Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. Plos One, 15(6), e0235021h. https://doi.org/10.1371/journal.pone.0235021
   Web of Science ®Google Scholar
• National Health Council. (n.d.). Fair-Market value calculator. Retrieved January 2, 2022, from https://nationalhealthcouncil.org/fair-market-value-calculator/
   Google Scholar
• Nelson, N. C., Keating, P., Cambrosio, A., Aguilar-Mahecha, A., & Basik, M. (2014). Testing devices or experimental systems? Cancer clinical trials take the genomic turn. Social Science & Medicine, 111, 74–83. https://doi.org/10.1016/j.socscimed.2014.04.008
   PubMed Web of Science ®Google Scholar
• Ocloo, J., & Matthews, R. (2016). From tokenism to empowerment: Progressing patient and public involvement in healthcare improvement. BMJ Quality & Safety, 25(8), 626–632. https://doi.org/10.1136/bmjqs-2015-004839
   PubMed Web of Science ®Google Scholar
• Oliver, S. R., Rees, R. W., Clarke-Jones, L., Milne, R., Oakley, A. R., Gabbay, J., Stein, K., Buchanan, P., & Gyte, G. (2008). A multidimensional conceptual framework for analysing public involvement in health services research. Health Expectations, 11(1), 72–84. https://doi.org/10.1111/j.1369-7625.2007.00476.x
   PubMed Web of Science ®Google Scholar
• Ozieranski, P., Rickard, E., & Mulinari, S. (2019). Exposing drug industry funding of UK patient organisations. The BMJ, l1806. https://doi.org/10.1136/bmj.l1806
   PubMedGoogle Scholar
• Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10(6), 428–438. https://doi.org/10.1038/nrd3405
   PubMed Web of Science ®Google Scholar
• PARADIGM. (n.d.). Testimonials. Retrieved February 1, 2022, from https://imi-paradigm.eu/testimonials/
   Google Scholar
• Patalano, F., Gutzwiller, F. S., Shah, B., Kumari, C., & Cook, N. S. (2020). Gathering structured patient insight to drive the PRO strategy in COPD: Patient-centric drug development from theory to practice. Advances in Therapy, 37(1), 17–26. https://doi.org/10.1007/s12325-019-01134-x
   PubMed Web of Science ®Google Scholar
• Patient Engagement Open Forum. (n.d.-a). Moving towards the integration 3 years of progress. Retrieved February 1, 2022, from https://patientengagementopenforum.org/wp-content/uploads/2020/11/PEOF2020_Description-Final-Session-Nov-23rd_final.pdf
   Google Scholar
• Patient Engagement Open Forum. (n.d.-b). Part two: Creating future patient engagement tools. Retrieved February 1, 2022, from https://patientengagementopenforum.org/wp-content/uploads/2019/08/SESSION-7_PART-2-CREATING-FUTURE-PATIENT-ENGAGEMENT-TOOLS.pdf
   Google Scholar
• Patient Engagement Open Forum. (n.d.-c). https://patientengagementopenforum.org
   Google Scholar
• Patient Engagement Open Forum. (n.d.-d). Patient Engagement Open Forum—Day 2 workshops. Retrieved February 1, 2022, from https://patientengagementopenforum.org/wp-content/uploads/2019/09/Workshop-1.pdf
   Google Scholar
• Patient Focused Medicines Development. (n.d.-a). Mission and strategy. Retrieved February 1, 2022, from https://patientfocusedmedicine.org/mission-and-strategy/
   Google Scholar
• Patient Focused Medicines Development. (n.d.-b). The digital solution patient engagement. https://pemsuite.org/synapse/
   Google Scholar
• Sams-Dodd, F. (2013). Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discovery Today, 18(5–6), 211–217. https://doi.org/10.1016/j.drudis.2012.10.010
   PubMed Web of Science ®Google Scholar
• Sismondo, S. (2009). Ghosts in the machine: Publication planning in the medical sciences. Social Studies of Science, 39(2), 171–198. https://doi.org/10.1177/0306312708101047
   PubMed Web of Science ®Google Scholar
• Sismondo, S. (2018). Ghost-managed medicine: Big pharma’s invisible hands. Mattering Press.
   Google Scholar
• Stergiopoulos, S., Michaels, D. L., Kunz, B. L., & Getz, K. A. (2019). Measuring the impact of patient engagement and patient centricity in clinical research and development. Therapeutic Innovation & Regulatory Science, 216847901881751. https://doi.org/10.1177/2168479018817517
   Web of Science ®Google Scholar
• Sygna, K., Johansen, S., & Ruland, C. M. (2015). Recruitment challenges in clinical research including cancer patients and their caregivers. A randomized controlled trial study and lessons learned. Trials, 16(1), 428. https://doi.org/10.1186/s13063-015-0948-y
   PubMedGoogle Scholar
• Thompson, A. G. H. (2007). The meaning of patient involvement and participation in health care consultations: A taxonomy. Social Science & Medicine, 64(6), 1297–1310. https://doi.org/10.1016/j.socscimed.2006.11.002
   PubMed Web of Science ®Google Scholar
• Vat, L., & Schuitmaker-Warnaar, T. J. (2021). Evaluation of patient engagement in medicine development: A multi-stakeholder framework with metrics. Health Expectations, 24(2), 491–506. https://doi.org/10.1111/hex.13191
   PubMed Web of Science ®Google Scholar
• Wilkes, M. S., Bell, R. A., & Kravitz, R. L. (2000). Direct-to-consumer prescription drug advertising: Trends, impact, and implications: Aiming drug ads at consumers means big business for drug companies, but its effect on clinical care is not yet known. Health Affairs, 19(2), 110–128. https://doi.org/10.1377/hlthaff.19.2.110
   PubMed Web of Science ®Google Scholar
• Zvonareva, O., Craveț, C., & Richards, D. P. (2022). Practices of patient engagement in drug development: A systematic scoping review. Research Involvement and Engagement, 8(1), 29. https://doi.org/10.1186/s40900-022-00364-8
   PubMedGoogle Scholar